

Supplementary Material

Utilisation of in-consultation supervisor assistance in general practice training and personal cost to trainees: a cross-sectional study

Nancy Sturman^A, Amanda Tapley^{B,C}, Elizabeth Holliday^B, Alison Fielding^{B,C}, Andrew Davey^{B,C}, Mieke van Driel^A, Jean Ball^D, Kristen FitzGerald^{E,F}, Neil Spike^{G,H,I} and Parker Magin^{B,C,}*

^AGeneral Practice Clinical Unit, Faculty of Medicine, University of Queensland, Level 8, Health Sciences Building, Royal Brisbane and Women's Hospital, Brisbane, Qld 4006, Australia

^BSchool of Medicine and Public Health, University of Newcastle, University Drive, Callaghan, Newcastle, NSW 2308, Australia

^CNSW and ACT Research and Evaluation Unit, GP Synergy, Regional Training Organisation, 20 McIntosh Drive, Mayfield West, NSW 2304, Australia

^DClinical Research Design and Statistical Support Unit, Hunter Medical Research Institute, New Lambton Heights, NSW 2305, Australia

^ESchool of Medicine, University of Tasmania, Level 1, Medical Science 1, 17 Liverpool Street, Hobart, Tas. 7000, Australia

^FGeneral Practice Training Tasmania, Regional Training Organisation, Level 3, RACT House, 179 Murray Street, Hobart, Tas. 7000, Australia

^GDepartment of General Practice and Primary Health Care, University of Melbourne, 200 Berkeley Street, Carlton, Vic. 3053, Australia

^HSchool of Rural Health, Faculty of Medicine, Nursing and Health Sciences, Monash University, Northways Road, Churchill, Vic. 3842, Australia

^IEastern Victoria General Practice Training, Regional Training Organisation, 15 Cato Street, Hawthorn, Vic. 3122, Australia

*Correspondence to: Email: Parker.Magin@newcastle.edu.au

Table S1: Study questionnaire - (Abridged – ‘Supervisor section’)
Registrar Practice and Registrar Projects Questionnaire

2018.1 [GP Synergy - HMCC]

“Supervisor” section

The following items relate to **supervision** in general practice.

19 Please indicate your level of agreement with each of the statements below by rating each item on the scale shown:

| | Strongly disagree | Disagree | Agree | Strongly agree |
|-------------------------------------------------------------------------------------------------|--------------------------|--------------------------|--------------------------|--------------------------|
| a) My current main GP supervisor encourages me to seek advice from him or her if I am uncertain | <input type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> |
| b) I am generally satisfied with the advice I obtain from my current main GP supervisor | <input type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> |

20. Please complete the following two sentences as to how you feel about your practice:

| | | | | | |
|---------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------|----------------------------------------------------------------|------------------------------------------------------------------|--------------------------------------------------------------|----------------------------------------------------------|
| a) When my current main GP supervisor gives me advice during the consultation, I feel the patient's assessment of my competence: | Decreases a lot <input type="checkbox"/> | Decreases somewhat <input type="checkbox"/> | Does not change <input type="checkbox"/> | Increases somewhat <input type="checkbox"/> | Increases a lot <input type="checkbox"/> |
| b) Compared to presenting to my current main GP supervisor in front of the patient, I find presenting their case outside the patient's hearing : | Much more uncomfortable <input type="checkbox"/> | Somewhat more uncomfortable <input type="checkbox"/> | No more or less uncomfortable <input type="checkbox"/> | Somewhat more comfortable <input type="checkbox"/> | Much more comfortable <input type="checkbox"/> |

21 When you obtain advice during the consultation from your current main GP supervisor, please rate how often you use the following methods:

| Methods of obtaining advice during the consultation | Never | Rarely | Sometimes | Often | Always |
|-------------------------------------------------------------------------------------------------|--------------------------|--------------------------|--------------------------|--------------------------|--------------------------|
| a) My supervisor interrupts his/her consultation and comes into my consulting room | <input type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> |
| b) My supervisor comes into my consulting room in between his/her own consultations | <input type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> |
| c) My supervisor and I talk by phone, from our own consulting rooms | <input type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> |
| d) My supervisor and I talk face-to-face or by phone, out of the patient's hearing | <input type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> |
| e) My supervisor and I communicate by an electronic messaging system from our desktop computers | <input type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> |
| f) Other (please specify): | | | | | |

Table S2: Factors associated with in-consultation trainee help-seeking from general practice supervisors

| Factor group | Variable | Class | In-consultation help-seeking | | |
|------------------|---------------------------------------------------------------|----------------------------|------------------------------|------------|--------|
| | | | No | Yes | p |
| Study factors | Perceived change in patient impressions of trainee competence | Increase or no change | 33000 (81%) | 4138 (79%) | 0.15 |
| | | Decrease | 7711 (19%) | 1122 (21%) | |
| | Relative trainee comfort presenting outside patient hearing | More uncomfortable or same | 18374 (45%) | 2455 (47%) | 0.42 |
| | | More comfortable | 22289 (55%) | 2793 (53%) | |
| Trainee factors | Trainee FT or PT | Part-time | 9153 (23%) | 1324 (26%) | 0.098 |
| | | Full-time | 31100 (77%) | 3855 (74%) | |
| | Trainee gender | Male | 17957 (42%) | 2037 (37%) | 0.005 |
| | | Female | 24480 (58%) | 3441 (63%) | |
| | Term | Term 1 | 25106 (59%) | 4260 (78%) | <0.001 |
| | | Term 2 | 4204 (10%) | 444 (8%) | |
| | | Term 3 | 13127 (31%) | 774 (14%) | |
| | Worked at practice previously | No | 37295 (89%) | 5123 (94%) | <0.001 |
| | | Yes | 4639 (11%) | 319 (6%) | |
| | Qualified as doctor in Australia | No | 7346 (17%) | 948 (17%) | 0.88 |
| | | Yes | 35067 (83%) | 4494 (83%) | |
| | Has previous health qualification | No | 36289 (86%) | 4651 (86%) | 0.71 |
| | | Yes | 5778 (14%) | 778 (14%) | |
| | Has post-grad medical qualification | No | 25892 (62%) | 3236 (60%) | 0.31 |
| | | Yes | 16128 (38%) | 2180 (40%) | |
| | Has other regular medical work | No | 35200 (83%) | 4630 (85%) | 0.25 |
| | | Yes | 7237 (17%) | 848 (15%) | |
| | Trainee age | mean (SD) | 33 (6) | 33 (7) | 0.43 |
| | Years worked as doctor prior to GP training | mean (SD) | 3 (3) | 3 (3) | 0.15 |
| Practice factors | Practice size | Small | 17387 (43%) | 2352 (46%) | 0.22 |
| | | Large | 22635 (57%) | 2787 (54%) | |
| | Rurality | Major city | 26782 (63%) | 3377 (62%) | 0.64 |
| | | Inner regional | 11315 (27%) | 1496 (27%) | |

| Factor group | Variable | Class | In-consultation help-seeking | | |
|----------------------|-------------------------------|-----------------------------------------------|------------------------------|------------|--------|
| | | | No | Yes | p |
| | Practice routinely bulk bills | Outer regional remote | 4285 (10%) | 600 (11%) | 0.36 |
| | | No | 25336 (60%) | 3361 (61%) | |
| | | Yes | 17048 (40%) | 2111 (39%) | |
| | SEIFA index | mean (SD) | 5 (3) | 5 (3) | 0.26 |
| Patient factors | Patient age group | 0-14 | 6775 (16%) | 919 (17%) | <0.001 |
| | | 35-64 | 15387 (37%) | 2006 (37%) | |
| | | 65+ | 7542 (18%) | 1112 (21%) | |
| | Patient gender | Male | 16752 (40%) | 2245 (42%) | 0.002 |
| | | Female | 24682 (60%) | 3078 (58%) | |
| | ATSI | No | 38460 (98%) | 4873 (98%) | 0.12 |
| | | Yes | 840 (2%) | 110 (2%) | |
| | NESB | No | 35057 (89%) | 4478 (89%) | 0.65 |
| | | Yes | 4400 (11%) | 561 (11%) | |
| | Patient/practice status | Existing patient of trainee | 14756 (36%) | 2114 (39%) | <0.001 |
| | | New patient for trainee but known to practice | 23036 (56%) | 2723 (51%) | |
| | | New patient for practice | 3707 (9%) | 524 (10%) | |
| Consultation factors | Chronic problem | No | 31534 (74%) | 3912 (71%) | 0.002 |
| | | Yes | 10903 (26%) | 1566 (29%) | |
| | Sought help (non-human) | No | 35066 (83%) | 4615 (84%) | <0.001 |
| | | Yes | 7371 (17%) | 863 (16%) | |
| | Consultation duration | mean (SD) | 18 (9) | 25 (12) | <0.001 |
| | Number of problems | mean (SD) | 2 (1) | 2 (1) | <0.001 |

STROBE Statement—checklist of items that should be included in reports of observational studies

| | Item No | Recommendation | Page No |
|--------------------------|---------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------|
| Title and abstract | 1 | (a) Indicate the study's design with a commonly used term in the title or the abstract | 1 |
| | | (b) Provide in the abstract an informative and balanced summary of what was done and what was found | 4-5 |
| Introduction | | | |
| Background/rationale | 2 | Explain the scientific background and rationale for the investigation being reported | 6-7 |
| Objectives | 3 | State specific objectives, including any prespecified hypotheses | 7 |
| Methods | | | |
| Study design | 4 | Present key elements of study design early in the paper | 8 |
| Setting | 5 | Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection | 7-8 (including reference to protocol paper) |
| Participants | 6 | (a) <i>Cohort study</i> —Give the eligibility criteria, and the sources and methods of selection of participants. Describe methods of follow-up <i>Case-control study</i> —Give the eligibility criteria, and the sources and methods of case ascertainment and control selection. Give the rationale for the choice of cases and controls <i>Cross-sectional study</i> —Give the eligibility criteria, and the sources and methods of selection of participants | 7-8 (including reference to protocol paper) |
| | | (b) <i>Cohort study</i> —For matched studies, give matching criteria and number of exposed and unexposed <i>Case-control study</i> —For matched studies, give matching criteria and the number of controls per case | N/A |
| Variables | 7 | Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable | 7-8 (including reference to protocol paper), 26-27 |
| Data sources/measurement | 8* | For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group | 7-8 (including reference to protocol paper) |
| Bias | 9 | Describe any efforts to address potential sources of bias | 8-9 |

| | | | |
|------------------------|----|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------|
| Study size | 10 | Explain how the study size was arrived at | 7-8 (included all eligible participants – a very large sample size of consultations, and no formal sample size /power calculations performed) |
| Quantitative variables | 11 | Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why | 9 |
| Statistical methods | 12 | (a) Describe all statistical methods, including those used to control for confounding | 8-9 |
| | | (b) Describe any methods used to examine subgroups and interactions | N/A – no sub-group analyses performed |
| | | (c) Explain how missing data were addressed | 9 |
| | | (d) <i>Cohort study</i> —If applicable, explain how loss to follow-up was addressed <i>Case-control study</i> —If applicable, explain how matching of cases and controls was addressed <i>Cross-sectional study</i> —If applicable, describe analytical methods taking account of sampling strategy | 9 (regression analyses were conducted within the GEE framework) |
| | | (e) Describe any sensitivity analyses | N/A – no sensitivity analyses performed |

Continued on next page

| | | | |
|--------------------------|-----|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------|
| Results | | | |
| Participants | 13* | (a) Report numbers of individuals at each stage of study—eg numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed | 10 |
| | | (b) Give reasons for non-participation at each stage | N/A (cross-sectional analysis and 96% response rate) |
| | | (c) Consider use of a flow diagram | N/A |
| Descriptive data | 14* | (a) Give characteristics of study participants (eg demographic, clinical, social) and information on exposures and potential confounders | 10, 20 |
| | | (b) Indicate number of participants with missing data for each variable of interest | 27 |
| | | (c) <i>Cohort study</i> —Summarise follow-up time (eg, average and total amount) | N/A (cohort study but analyses reported are cross-sectional) |
| Outcome data | 15* | <i>Cohort study</i> —Report numbers of outcome events or summary measures over time | |
| | | <i>Case-control study</i> —Report numbers in each exposure category, or summary measures of exposure | |
| | | <i>Cross-sectional study</i> —Report numbers of outcome events or summary measures | 10 |
| Main results | 16 | (a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (eg, 95% confidence interval). Make clear which confounders were adjusted for and why they were included | 10, 21-22 |
| | | (b) Report category boundaries when continuous variables were categorized | Protocol paper |
| | | (c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period | N/A |
| Other analyses | 17 | Report other analyses done—eg analyses of subgroups and interactions, and sensitivity analyses | N/A |
| Discussion | | | |
| Key results | 18 | Summarise key results with reference to study objectives | 11 |
| Limitations | 19 | Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss both direction and magnitude of any potential bias | 12-13 |
| Interpretation | 20 | Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence | 11-14 |
| Generalisability | 21 | Discuss the generalisability (external validity) of the study results | 13 |
| Other information | | | |
| Funding | 22 | Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based | 15 |

*Give information separately for cases and controls in case-control studies and, if applicable, for exposed and unexposed groups in cohort and cross-sectional studies.

Note: An Explanation and Elaboration article discusses each checklist item and gives methodological background and published examples of transparent reporting. The STROBE checklist is best used in conjunction with this article (freely available on the Web sites of PLoS Medicine at <http://www.plosmedicine.org/>, Annals of Internal Medicine at <http://www.annals.org/>, and Epidemiology at <http://www.epidem.com/>). Information on the STROBE Initiative is available at www.strobe-statement.org.